Metformin pretreatment reduces effect to dacarbazine and suppresses melanoma cell resistance

Metformin Treatment Suppresses Melanoma Cell Growth and Motility Through Modulation of microRNA Expression

(2019) Hui-Wen Tseng et al.   Cancers

Metformin prevention of doxorubicin resistance in MCF-7 and MDA-MB-231 involves oxidative stress generation and modulation of cell adaptation genes

(2019) Poliana Camila Marinello et al.   Scientific Reports

Prognostic significance of 8-hydroxy-2′-deoxyguanosine in solid tumors: a meta-analysis

(2019) Xiangcheng Qing et al.   BMC CANCER

Valproic acid sensitizes metformin-resistant human renal cell carcinoma cells by upregulating H3 acetylation and EMT reversal

(2018) Muyun Wei et al.   BMC CANCER

Metformin sensitizes endometrial cancer cells to chemotherapy through IDH1-induced Nrf2 expression via an epigenetic mechanism

(2018) Mingzhu Bai et al.   ONCOGENE

Tribromophenol affects the metabolism, proliferation, migration and multidrug resistance transporters activity of murine melanoma cells B16F1

(2018) Yvanna Carla de Souza Salgado et al.   TOXICOLOGY IN VITRO

Glucose metabolism and NRF2 coordinate the antioxidant response in melanoma resistant to MAPK inhibitors

(2018) Raeeka Khamari et al.   Cell Death & Disease

Metformin increases antitumor activity of MEK inhibitor binimetinib in 2D and 3D models of human metastatic melanoma cells

(2018) Oxana Ryabaya et al.   BIOMEDICINE & PHARMACOTHERAPY

Metformin synergistically enhances the antitumor activity of the third-generation EGFR-TKI CO-1686 in lung cancer cells through suppressing NF-κB signaling

(2018) Yong-Hong Pan et al.   Clinical Respiratory Journal

NRF2 and NF-қB interplay in cerebrovascular and neurodegenerative disorders: Molecular mechanisms and possible therapeutic approaches

(2018) Farzane Sivandzade et al.   Redox Biology

Function and Clinical Implications of Long Non-Coding RNAs in Melanoma

(2017) Georg Richtig et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Metformin

(2017) Fernando P. de Souza Neto et al.   MELANOMA RESEARCH

ΔNp73 regulates the expression of the multidrug-resistance genes ABCB1 and ABCB5 in breast cancer and melanoma cells - a short report

(2017) Habib A. M. Sakil et al.   CELLULAR ONCOLOGY

Metformin sensitizes lung cancer cells to treatment by the tyrosine kinase inhibitor erlotinib

(2017) Xiaofei Wang et al.   Oncotarget

Targeting the NF-κB pathway in prostate cancer: a promising therapeutic approach?

(2016) Daniela Verzella et al.   CURRENT DRUG TARGETS

The phenomenon of acquired resistance to metformin in breast cancer cells: The interaction of growth pathways and estrogen receptor signaling

(2016) Alexander M. Scherbakov et al.   IUBMB LIFE

In Vivo Imaging of Human 11C-Metformin in Peripheral Organs: Dosimetry, Biodistribution, and Kinetic Analyses

(2016) L. C. Gormsen et al.   JOURNAL OF NUCLEAR MEDICINE

ROS homeostasis and metabolism: a dangerous liason in cancer cells

(2016) E Panieri et al.   Cell Death & Disease

The role of p53 in cancer drug resistance and targeted chemotherapy

(2016) Karin Hientz et al.   Oncotarget

Metformin sensitizes the response of oral squamous cell carcinoma to cisplatin treatment through inhibition of NF-κB/HIF-1α signal axis

(2016) Xiaofeng Qi et al.   Scientific Reports

Metformin targets Axl and Tyro3 receptor tyrosine kinases to inhibit cell proliferation and overcome chemoresistance in ovarian cancer cells

(2015) NAM-YI KIM et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Metformin Antagonizes Cancer Cell Proliferation by Suppressing Mitochondrial-Dependent Biosynthesis

(2015) Takla Griss et al.   PLOS BIOLOGY

Mitochondrial oxidative stress is the achille’s heel of melanoma cells resistant to Braf-mutant inhibitor

(2015) Paola Corazao-Rozas et al.   Oncotarget

Deficiency in p53 is required for doxorubicin induced transcriptional activation of NF-кB target genes in human breast cancer

(2015) Alba Dalmases et al.   Oncotarget

Binding mode and thermodynamic studies on the interaction of the anticancer drug dacarbazine and dacarbazine–Cu(II) complex with single and double stranded DNA

(2014) Yassien Temerk et al.   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Penile primary melanoma: analysis of 6 patients treated at Brazilian national cancer institute in the last eight years

(2014) Gustavo Ruschi Bechara et al.   International Braz J Urol

p53 is necessary for the adaptive changes in cellular milieu subsequent to an acute bout of endurance exercise

(2013) Ayesha Saleem et al.   AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY

Metformin Enhances Cisplatin Cytotoxicity by Suppressing Signal Transducer and Activator of Transcription–3 Activity Independently of the Liver Kinase B1–AMP-Activated Protein Kinase Pathway

(2013) Chien-Chung Lin et al.   AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY

Functions, divergence and clinical value of TAp73 isoforms in cancer

(2013) Stella Logotheti et al.   CANCER AND METASTASIS REVIEWS

p63 is an alternative p53 repressor in melanoma that confers chemoresistance and a poor prognosis

(2013) Rubeta N. Matin et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Metformin Blocks Melanoma Invasion and Metastasis Development in AMPK/p53-Dependent Manner

(2013) M. Cerezo et al.   MOLECULAR CANCER THERAPEUTICS

Toward clinical application of the Keap1–Nrf2 pathway

(2013) Takafumi Suzuki et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Decreased oxidant profile and increased antioxidant capacity in naturally postmenopausal women

(2012) V. J. Victorino et al.   AGE

Antileukemic effects of AMPK activators on BCR-ABL-expressing cells

(2011) E. Vakana et al.   BLOOD

Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro

(2011) Irina N. Alimova et al.   CELL CYCLE

AMP-dependent kinase/mammalian target of rapamycin complex 1 signaling in T-cell acute lymphoblastic leukemia: therapeutic implications

(2011) C Grimaldi et al.   LEUKEMIA

Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis

(2011) Gina M. DeNicola et al.   NATURE

Metformin inhibits melanoma development through autophagy and apoptosis mechanisms

(2011) T Tomic et al.   Cell Death & Disease

Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K

(2010) Jessie Villanueva et al.   CANCER CELL

Oxidative stress, inflammation, and cancer: How are they linked?

(2010) Simone Reuter et al.   FREE RADICAL BIOLOGY AND MEDICINE

Metformin in Cancer Therapy: A New Perspective for an Old Antidiabetic Drug?

(2010) I. Ben Sahra et al.   MOLECULAR CANCER THERAPEUTICS

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

(2010) Ramin Nazarian et al.   NATURE

Diet and tumor LKB1 expression interact to determine sensitivity to anti-neoplastic effects of metformin in vivo

(2010) C Algire et al.   ONCOGENE

Putative chemopreventive molecules can increase Nrf2-regulated cell defense in some human cancer cell lines, resulting in resistance to common cytotoxic therapies

(2009) Liangao Hu et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Watching the watcher: regulation of p53 by mitochondria

(2009) Aaron K Holley et al.   Future Oncology

Characterization of genome-wide p53-binding sites upon stress response

(2008) Leonie Smeenk et al.   NUCLEIC ACIDS RESEARCH

The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level

(2008) I Ben Sahra et al.   ONCOGENE

Role of p53 in mitochondrial biogenesis and apoptosis in skeletal muscle

(2008) Ayesha Saleem et al.   PHYSIOLOGICAL GENOMICS

Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy

(2008) T. Shibata et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA